Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

Results from survey of Urea Cycle Disorders (UCD) healthcare providers show taste and odor were the most important attributes when considering treatment options and treatment adherence

NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced data was presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) at the 44^th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD), March 18^th-21^st in Salt Lake City, Utah. Results from the discrete choice experiment presented showed that taste and odor were the most important attributes, as identified by UCD healthcare providers, that influence overall prescription of, and patient adherence to, UCD treatments when evaluating nitrogen-binding medications (such as sodium phenylbutyrate and glycerol phenylbutyrate).

“Nitrogen-binding medications, such as sodium phenylbutyrate or glycerol phenylbutyrate, can be efficacious in the treatment of UCDs if patients are adherent to their prescribed treatment^1,2,” stated Robert Steiner, M.D., Professor at the University of Wisconsin School of Medicine and Public Health. “However, 25% of life-threatening hyperammonemic crises in patients with UCDs may be precipitated by a lack of adherence to medications and/or diet and certain attributes of existing nitrogen-binding medications may negatively impact adherence³. Given these results, alternative treatment options are urgently needed.”

Healthcare Provider UCD Treatment Preference Data Presented at SIMD 2023
A copy of the poster presentation from the 2023 SIMD Meeting is available on Acer’s website at: https://www.acertx.com/wp-content/uploads/2023/03/2023-SIMD-DCE-Poster ...

Poster #97: Quantifying Preferences for Urea Cycle Disorder Treatments Using a Discrete-Choice Experiment⁴
This poster presented at SIMD summarizes results from a web-based, quantitative survey study conducted on Acer’s behalf, using a discrete choice experiment (DCE) methodology. This study was designed to quantify the most-desired product attributes that may influence overall prescription of, and patient adherence to, nitrogen-binding medications (such as sodium phenylbutyrate and glycerol phenylbutyrate) for the treatment of UCDs as identified by the survey participants.